Completed PHASE4 INTERVENTIONAL 2-arm NCT00930943

Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning

Effect of Extended-release Oxymorphone Hydrochloride (Opana® ER), Taken Fasting Versus With Food, on Cognitive Functioning in Opioid-tolerant Subjects: a Randomized, Single-blinded, Cross-over Study

Sponsor: MedVadis Research Corporation

Conditions Chronic Pain

Interventions Oxymorphone ER

Updated 8 times since 2017 Last updated: May 8, 2023 Started: May 31, 2009 Primary completion: Nov 30, 2009 Completion: Nov 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Chronic Pain, this trial is completed. The trial is conducted by MedVadis Research Corporation and has accumulated 8 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE4
Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jun 2023 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Jun 2023 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

May 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MedVadis Research Corporation

Data source: MedVadis Research Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wellesley Hills, United States